Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Burden of disease matters when it comes to systemic therapy for prostate cancer.

Harrison MR, Armstrong AJ.

Eur Urol. 2015 Mar;67(3):448-50. doi: 10.1016/j.eururo.2014.02.032. Epub 2014 Feb 22. No abstract available.

PMID:
24612662
4.

Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.

Azad AA, Eigl BJ, Leibowitz-Amit R, Lester R, Kollmannsberger C, Murray N, Clayton R, Heng DY, Joshua AM, Chi KN.

Eur Urol. 2015 Mar;67(3):441-7. doi: 10.1016/j.eururo.2014.01.030. Epub 2014 Jan 31.

PMID:
24508071
5.

Osteoclast inhibitors in advanced prostate cancer: does the benefit extend beyond skeletal-related events?

Geynisman DM, Ross EA, Plimack ER.

Eur Urol. 2015 Oct;68(4):578-80. doi: 10.1016/j.eururo.2015.06.009. Epub 2015 Jun 23. No abstract available.

PMID:
26116295
6.

Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.

Petrioli R, Francini E, Laera L, Fiaschi AI, Ponchietti R, Roviello G.

Cancer Chemother Pharmacol. 2015 Sep;76(3):439-45. doi: 10.1007/s00280-015-2803-y. Epub 2015 Jun 17. Review.

PMID:
26082421
7.

Beyond approval: what is the most appropriate way to use the expanding Armamentarium in metastatic castration-resistant prostate cancer and how do we move forward?

Suzman D, Eisenberger M.

Eur Urol. 2014 Nov;66(5):826-8. doi: 10.1016/j.eururo.2014.03.046. Epub 2014 Apr 13. No abstract available.

PMID:
24751214
8.

Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer.

Arrabal-Martín M, Anglada-Curado F, Cózar-Olmo JM, Soler-Martínez J, Moreno-Jiménez J, Castiñeiras-Fernández J, Ledo-Cepero MJ, Beardo-Villar P, Requena-Tapia MJ, Zuluaga-Gómez A; Grupo AAyEU.

Actas Urol Esp. 2014 Jun;38(5):327-33. doi: 10.1016/j.acuro.2013.10.008. Epub 2013 Dec 15. Review. English, Spanish.

PMID:
24342031
9.

A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.

Azad AA, Leibowitz-Amit R, Eigl BJ, Lester R, Wells JC, Murray RN, Kollmannsberger C, Heng DY, Joshua AM, Chi KN.

Prostate. 2014 Nov;74(15):1544-50. doi: 10.1002/pros.22872. Epub 2014 Aug 29.

PMID:
25175831
10.

Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer.

Harshman LC, Taplin ME.

Adv Ther. 2013 Aug;30(8):727-47. doi: 10.1007/s12325-013-0050-3. Epub 2013 Aug 27. Review.

12.
13.

Intermittent androgen deprivation therapy: clarity from confusion.

Klotz L.

Eur Urol. 2013 Nov;64(5):731-3. doi: 10.1016/j.eururo.2013.06.038. Epub 2013 Jun 28. No abstract available.

PMID:
23866956
15.

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS.

J Clin Oncol. 2009 Aug 10;27(23):3742-8. doi: 10.1200/JCO.2008.20.0642. Epub 2009 May 26.

16.

Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer.

Auchus RJ, Yu MK, Nguyen S, Mundle SD.

Oncologist. 2014 Dec;19(12):1231-40. doi: 10.1634/theoncologist.2014-0167. Epub 2014 Oct 31. Review.

18.

Recent patents on new steroid agents targeting the steroidogenesis for endocrine cancer treatments.

Poirier D.

Recent Pat Endocr Metab Immune Drug Discov. 2015;9(1):15-23. Review.

PMID:
25643356
19.

[New therapies in metastatic castration resistant prostate cancer].

Thibault C, Massard C.

Bull Cancer. 2015 Jun;102(6):501-8. doi: 10.1016/j.bulcan.2015.04.016. Epub 2015 May 26. Review. French.

PMID:
26022286
20.

[Advances in the treatment of castration-resistant prostate cancer: emphasis in new hormonal therapies].

Berlin A, Fernández MI.

Rev Med Chil. 2015 Feb;143(2):223-36. doi: 10.4067/S0034-98872015000200010. Review. Spanish.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk